Elucidation of the effect of plumbagin on the metastatic potential of B16F10 murine melanoma cells via MAPK signalling pathway
Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoq...
Saved in:
Published in | Experimental dermatology Vol. 29; no. 4; pp. 427 - 435 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Denmark
Wiley Subscription Services, Inc
01.04.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoquinone (5‐hydroxy‐2‐methyl‐1, 4‐naphthoquinone), isolated from the roots of medicinal plant Plumbago zeylanica, and it is widely present in Lawsonia inermis L. It has been shown that plumbagin has an anti‐proliferative and anti‐invasive activities in various cancer cell lines; however, the anti‐cancer and anti‐metastatic effects of plumbagin are largely unknown against melanoma cells. In this study, we evaluated the effect of plumbagin on B16F10 murine melanoma cells . Plumbagin decreased B16F10 cell viability as well as the cell migration, adhesion, and invasion. The molecular mechanism was studied, and plumbagin downregulated genes relevant in MAPK pathway, matrix metalloproteinases (MMP's), and cell adhesion. Furthermore, plumbagin elevated the expression of apoptosis and tumors suppressor genes, and genes significant in reactive oxygen species (ROS) response. Taken together, our findings suggest that plumbagin has an anti‐invasion and anti‐metastasis effect on melanoma cancer cells by acting on MAPK pathway and its related genes. |
---|---|
AbstractList | Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoquinone (5‐hydroxy‐2‐methyl‐1, 4‐naphthoquinone), isolated from the roots of medicinal plant Plumbago zeylanica, and it is widely present in Lawsonia inermis L. It has been shown that plumbagin has an anti‐proliferative and anti‐invasive activities in various cancer cell lines; however, the anti‐cancer and anti‐metastatic effects of plumbagin are largely unknown against melanoma cells. In this study, we evaluated the effect of plumbagin on B16F10 murine melanoma cells . Plumbagin decreased B16F10 cell viability as well as the cell migration, adhesion, and invasion. The molecular mechanism was studied, and plumbagin downregulated genes relevant in MAPK pathway, matrix metalloproteinases (MMP's), and cell adhesion. Furthermore, plumbagin elevated the expression of apoptosis and tumors suppressor genes, and genes significant in reactive oxygen species (ROS) response. Taken together, our findings suggest that plumbagin has an anti‐invasion and anti‐metastasis effect on melanoma cancer cells by acting on MAPK pathway and its related genes. Abstract Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoquinone (5‐hydroxy‐2‐methyl‐1, 4‐naphthoquinone), isolated from the roots of medicinal plant Plumbago zeylanica, and it is widely present in Lawsonia inermis L . It has been shown that plumbagin has an anti‐proliferative and anti‐invasive activities in various cancer cell lines; however, the anti‐cancer and anti‐metastatic effects of plumbagin are largely unknown against melanoma cells. In this study, we evaluated the effect of plumbagin on B16F10 murine melanoma cells . Plumbagin decreased B16F10 cell viability as well as the cell migration, adhesion, and invasion. The molecular mechanism was studied, and plumbagin downregulated genes relevant in MAPK pathway, matrix metalloproteinases (MMP's), and cell adhesion. Furthermore, plumbagin elevated the expression of apoptosis and tumors suppressor genes, and genes significant in reactive oxygen species (ROS) response. Taken together, our findings suggest that plumbagin has an anti‐invasion and anti‐metastasis effect on melanoma cancer cells by acting on MAPK pathway and its related genes. Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply and form malignant tumors. The current therapy is limited by the highly ability of this disease to metastasize rapidly. Plumbagin is a naphthoquinone (5-hydroxy-2-methyl-1, 4-naphthoquinone), isolated from the roots of medicinal plant Plumbago zeylanica, and it is widely present in Lawsonia inermis L. It has been shown that plumbagin has an anti-proliferative and anti-invasive activities in various cancer cell lines; however, the anti-cancer and anti-metastatic effects of plumbagin are largely unknown against melanoma cells. In this study, we evaluated the effect of plumbagin on B16F10 murine melanoma cells . Plumbagin decreased B16F10 cell viability as well as the cell migration, adhesion, and invasion. The molecular mechanism was studied, and plumbagin downregulated genes relevant in MAPK pathway, matrix metalloproteinases (MMP's), and cell adhesion. Furthermore, plumbagin elevated the expression of apoptosis and tumors suppressor genes, and genes significant in reactive oxygen species (ROS) response. Taken together, our findings suggest that plumbagin has an anti-invasion and anti-metastasis effect on melanoma cancer cells by acting on MAPK pathway and its related genes. |
Author | Alem, Fatima‐Zahra Rhourri‐Frih, Boutayna Bejaoui, Meriem Villareal, Myra O. Isoda, Hiroko |
Author_xml | – sequence: 1 givenname: Fatima‐Zahra surname: Alem fullname: Alem, Fatima‐Zahra organization: CNRS UMR 5248 – sequence: 2 givenname: Meriem orcidid: 0000-0002-0607-6562 surname: Bejaoui fullname: Bejaoui, Meriem organization: University of Tsukuba – sequence: 3 givenname: Myra O. orcidid: 0000-0003-4338-3323 surname: Villareal fullname: Villareal, Myra O. organization: University of Tsukuba – sequence: 4 givenname: Boutayna surname: Rhourri‐Frih fullname: Rhourri‐Frih, Boutayna organization: CNRS UMR 5248 – sequence: 5 givenname: Hiroko orcidid: 0000-0002-1399-9541 surname: Isoda fullname: Isoda, Hiroko email: isoda.hiroko.ga@u.tsukuba.ac.jp organization: University of Tsukuba |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32012353$$D View this record in MEDLINE/PubMed |
BookMark | eNp10bFu1TAUBmALFdHbloEXQJZY6JD2OI6deCzlFlCLygASW-Q49q0rx05jh_YuPDtOb2GohBfLOp9-Hfk_QHs-eI3QGwInJJ9T_dCfkApq8QKtCAcogJdsD61AAC94DWwfHcR4C0BqWrNXaJ-WQErK6Ar9XrtZ2V4mGzwOBqcbjbUxWqXlNbp56OTG5pF_HA06yZiyVngMSftkpVvgB8IvCOBhnqxflJM-DBIr7VzEv6zEX8--XeJoN146Z_0GjzLd3MvtEXpppIv69dN9iH5crL-ffy6urj99OT-7KlTeUhSlUKLuqqYUknd9U8meSMM60VRMNZyXouuNrhg1DasZENmpHhSTPQVuKqVreoje73LHKdzNOqZ2sHHZTnod5tjmzwBBgFc803fP6G2Yp7z3ohrBgFEKWR3vlJpCjJM27TjZQU7blkC7lNLmUtrHUrJ9-5Q4d4Pu_8m_LWRwugP31unt_5Pa9c-Pu8g_UTyXXg |
CitedBy_id | crossref_primary_10_3390_pharmaceutics13050706 crossref_primary_10_2174_1389557520666201116144421 crossref_primary_10_1039_D3DT03806H crossref_primary_10_2174_1568026623666230901124059 crossref_primary_10_1097_CMR_0000000000000873 |
Cites_doi | 10.1016/j.jdermsci.2004.03.002 10.18632/oncotarget.5380 10.1039/C8RA05339A 10.1016/j.fct.2018.11.040 10.2147/CMAR.S6073 10.1016/j.fct.2019.01.018 10.1200/JCO.1999.17.7.2105 10.1016/j.devcel.2010.05.012 10.1002/jcb.22248 10.1038/sj.bjc.6603291 10.1056/NEJMoa1003466 10.1111/j.1742-4658.2012.08589.x 10.1371/journal.pone.0045023 10.1038/nrc1524 10.1021/acs.jnatprod.8b00964 10.1146/annurev-pathol-012513-104658 10.1038/nm1087 10.1158/1541-7786.MCR-08-0366 10.1016/j.intimp.2005.10.003 10.18632/oncotarget.4114 10.1186/s40360-016-0104-7 10.3389/fphar.2018.00856 10.1186/s12885-017-3892-2 10.1016/j.biopha.2018.02.052 10.1007/s00109-016-1452-x 10.1007/s10585-018-9893-y 10.1007/s00018-011-0878-0 10.1074/jbc.M112.421495 10.1101/gad.191999.112 10.1158/1541-7786.MCR-18-0327 10.1016/j.intimp.2009.03.022 10.2174/18715206113136660369 10.1242/jcs.092882 10.3109/09546634.2013.813897 10.1016/j.fitote.2004.03.009 10.3322/caac.21551 10.3390/ijms18020320 10.1038/nature12213 10.1046/j.1523-1747.2000.00068.x 10.1016/j.jep.2011.06.035 10.1111/bjd.15510 10.1177/1947601910373795 10.1093/nar/gkn923 |
ContentType | Journal Article |
Copyright | 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
DBID | NPM AAYXX CITATION 7T5 H94 7X8 |
DOI | 10.1111/exd.14079 |
DatabaseName | PubMed CrossRef Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts CrossRef PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1600-0625 |
EndPage | 435 |
ExternalDocumentID | 10_1111_exd_14079 32012353 EXD14079 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: Japan Student Services Organization (JASSO) – fundername: University of Tsukuba |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YUY ZZTAW ~IA ~WT NPM AAYXX CITATION 7T5 H94 7X8 |
ID | FETCH-LOGICAL-c3539-29c97b4829a6bd84ad1af5b9845c86629bdfe453f857501abcd0c5ad306f4ce73 |
IEDL.DBID | DR2 |
ISSN | 0906-6705 |
IngestDate | Fri Aug 16 02:08:52 EDT 2024 Thu Oct 10 16:20:38 EDT 2024 Fri Aug 23 00:33:22 EDT 2024 Sat Sep 28 08:28:37 EDT 2024 Sat Aug 24 01:07:16 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | MAPK pathway migration plumbagin adhesion invasion metastasis |
Language | English |
License | 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3539-29c97b4829a6bd84ad1af5b9845c86629bdfe453f857501abcd0c5ad306f4ce73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-4338-3323 0000-0002-1399-9541 0000-0002-0607-6562 |
PMID | 32012353 |
PQID | 2389505330 |
PQPubID | 2045157 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2350910646 proquest_journals_2389505330 crossref_primary_10_1111_exd_14079 pubmed_primary_32012353 wiley_primary_10_1111_exd_14079_EXD14079 |
PublicationCentury | 2000 |
PublicationDate | April 2020 2020-Apr 2020-04-00 20200401 |
PublicationDateYYYYMMDD | 2020-04-01 |
PublicationDate_xml | – month: 04 year: 2020 text: April 2020 |
PublicationDecade | 2020 |
PublicationPlace | Denmark |
PublicationPlace_xml | – name: Denmark – name: Chichester |
PublicationTitle | Experimental dermatology |
PublicationTitleAlternate | Exp Dermatol |
PublicationYear | 2020 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2011; 137 2019; 2019 2015; 6 2006; 95 2000; 115 2010; 18 2018; 101 2010; 363 2019; 17 2013; 288 2014; 25 2006; 6 2019; 125 2017; 177 2012; 125 2016; 17 2019; 123 2004; 10 2017; 95 2018; 18 2018; 9 2004; 75 2018; 8 2019; 82 2010; 1 2002; 62 2004; 36 1999; 17 2017; 10 2005; 5 2013; 499 2009; 9 2014; 14 2009; 7 2017; 18 2012; 26 2012; 279 2012; 69 2009; 108 2010; 2 2012; 7 2016; 9 2009; 37 2018; 35 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 Bastian A. (e_1_2_7_37_1) 2017; 10 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 Brose M. S. (e_1_2_7_10_1) 2002; 62 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_46_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_38_1 e_1_2_7_39_1 |
References_xml | – volume: 7 start-page: 601 year: 2009 publication-title: Mol. Cancer Res. – volume: 363 start-page: 711 year: 2010 publication-title: N. Engl. J. Med. – volume: 499 start-page: 214 year: 2013 publication-title: Nature – volume: 26 start-page: 1131 year: 2012 publication-title: Genes Dev. – volume: 177 start-page: 134 year: 2017 publication-title: Br. J. Dermatol. – volume: 10 start-page: 5772 year: 2017 publication-title: Role Matrix Met Hum. Body Pathol. – volume: 8 start-page: 32022 year: 2018 publication-title: RSC Adv. – volume: 9 start-page: 949 year: 2009 publication-title: Int. Immunopharmacol. – volume: 95 start-page: 53 year: 2017 publication-title: J. Mol. Med. – volume: 14 start-page: 170 year: 2014 publication-title: Anticancer Agents Med. Chem. – volume: 6 start-page: 20636 year: 2015 publication-title: Oncotarget – volume: 82 start-page: 878 year: 2019 publication-title: J. Nat. Prod. – volume: 137 start-page: 752 year: 2011 publication-title: J. Ethnopharmacol. – volume: 69 start-page: 1475 year: 2012 publication-title: Cell Mol. Life Sci. – volume: 17 start-page: 199 year: 2019 publication-title: Mol. Cancer Res. – volume: 2 start-page: 197 year: 2010 publication-title: Cancer Manag. Res. – volume: 123 start-page: 492 year: 2019 publication-title: Food Chem. Toxicol. – volume: 7 year: 2012 publication-title: PLoS ONE – volume: 18 start-page: 884 year: 2010 publication-title: Dev. Cell – volume: 9 start-page: 1 year: 2018 publication-title: Front. Pharmacol. – volume: 25 start-page: 401 year: 2014 publication-title: J. Dermatolog. Treat. – volume: 5 start-page: 51 year: 2005 publication-title: Nat. Rev. Cancer – volume: 1 start-page: 409 year: 2010 publication-title: Genes Cancer – volume: 10 start-page: 789 year: 2004 publication-title: Nat. Med. – volume: 18 start-page: 1 year: 2018 publication-title: BMC Cancer – volume: 125 start-page: 1693 year: 2012 publication-title: J. Cell Sci. – volume: 75 start-page: 500 year: 2004 publication-title: Fitoterapia – volume: 115 start-page: 337 year: 2000 publication-title: J. Invest. Dermatol. – volume: 18 start-page: 320 year: 2017 publication-title: Int. J. Mol. Sci. – volume: 35 start-page: 379 year: 2018 publication-title: Clin. Exp. Metastasis – volume: 108 start-page: 272 year: 2009 publication-title: J. Cell Biochem. – volume: 279 start-page: 2047 year: 2012 publication-title: FEBS J. – volume: 17 start-page: 1 year: 2016 publication-title: BMC Pharmacol. Toxicol. – volume: 101 start-page: 379 year: 2018 publication-title: Biomed Pharmacother. – volume: 17 start-page: 2105 year: 1999 publication-title: J. Clin. Oncol. – volume: 125 start-page: 566 year: 2019 publication-title: Food Chem. Toxicol. – volume: 6 start-page: 697 year: 2006 publication-title: Int. Immunopharmacol. – volume: 6 start-page: 38934 year: 2015 publication-title: Oncotarget – volume: 9 start-page: 239 year: 2016 – volume: 288 start-page: 6451 year: 2013 publication-title: J. Biol. Chem. – volume: 2019 start-page: 7 year: 2019 publication-title: CA Cancer J. Clin. – volume: 36 start-page: 71 year: 2004 publication-title: J. Dermatol. Sci. – volume: 95 start-page: 581 year: 2006 publication-title: Br. J. Cancer – volume: 62 start-page: 6997 year: 2002 publication-title: Cancer Res. – volume: 37 start-page: 1 year: 2009 publication-title: Nucleic Acids Res. – ident: e_1_2_7_14_1 doi: 10.1016/j.jdermsci.2004.03.002 – ident: e_1_2_7_35_1 doi: 10.18632/oncotarget.5380 – ident: e_1_2_7_40_1 doi: 10.1039/C8RA05339A – ident: e_1_2_7_21_1 doi: 10.1016/j.fct.2018.11.040 – volume: 62 start-page: 6997 year: 2002 ident: e_1_2_7_10_1 publication-title: Cancer Res. contributor: fullname: Brose M. S. – ident: e_1_2_7_16_1 doi: 10.2147/CMAR.S6073 – ident: e_1_2_7_46_1 doi: 10.1016/j.fct.2019.01.018 – ident: e_1_2_7_15_1 doi: 10.1200/JCO.1999.17.7.2105 – ident: e_1_2_7_28_1 doi: 10.1016/j.devcel.2010.05.012 – ident: e_1_2_7_12_1 doi: 10.1002/jcb.22248 – ident: e_1_2_7_34_1 doi: 10.1038/sj.bjc.6603291 – ident: e_1_2_7_5_1 doi: 10.1056/NEJMoa1003466 – ident: e_1_2_7_13_1 doi: 10.1111/j.1742-4658.2012.08589.x – ident: e_1_2_7_41_1 doi: 10.1371/journal.pone.0045023 – ident: e_1_2_7_26_1 doi: 10.1038/nrc1524 – ident: e_1_2_7_22_1 doi: 10.1021/acs.jnatprod.8b00964 – ident: e_1_2_7_9_1 doi: 10.1146/annurev-pathol-012513-104658 – ident: e_1_2_7_31_1 doi: 10.1038/nm1087 – ident: e_1_2_7_32_1 doi: 10.1158/1541-7786.MCR-08-0366 – ident: e_1_2_7_27_1 doi: 10.1016/j.intimp.2005.10.003 – ident: e_1_2_7_44_1 doi: 10.18632/oncotarget.4114 – ident: e_1_2_7_29_1 doi: 10.1186/s40360-016-0104-7 – ident: e_1_2_7_39_1 doi: 10.3389/fphar.2018.00856 – ident: e_1_2_7_3_1 doi: 10.1186/s12885-017-3892-2 – ident: e_1_2_7_18_1 doi: 10.1016/j.biopha.2018.02.052 – ident: e_1_2_7_36_1 doi: 10.1007/s00109-016-1452-x – ident: e_1_2_7_2_1 doi: 10.1007/s10585-018-9893-y – ident: e_1_2_7_45_1 doi: 10.1007/s00018-011-0878-0 – ident: e_1_2_7_38_1 doi: 10.1074/jbc.M112.421495 – ident: e_1_2_7_24_1 doi: 10.1101/gad.191999.112 – ident: e_1_2_7_33_1 doi: 10.1158/1541-7786.MCR-18-0327 – ident: e_1_2_7_19_1 doi: 10.1016/j.intimp.2009.03.022 – volume: 10 start-page: 5772 year: 2017 ident: e_1_2_7_37_1 publication-title: Role Matrix Met Hum. Body Pathol. contributor: fullname: Bastian A. – ident: e_1_2_7_42_1 doi: 10.2174/18715206113136660369 – ident: e_1_2_7_43_1 doi: 10.1242/jcs.092882 – ident: e_1_2_7_17_1 doi: 10.3109/09546634.2013.813897 – ident: e_1_2_7_30_1 doi: 10.1016/j.fitote.2004.03.009 – ident: e_1_2_7_6_1 doi: 10.3322/caac.21551 – ident: e_1_2_7_20_1 doi: 10.3390/ijms18020320 – ident: e_1_2_7_7_1 doi: 10.1038/nature12213 – ident: e_1_2_7_11_1 doi: 10.1046/j.1523-1747.2000.00068.x – ident: e_1_2_7_25_1 doi: 10.1016/j.jep.2011.06.035 – ident: e_1_2_7_4_1 doi: 10.1111/bjd.15510 – ident: e_1_2_7_8_1 doi: 10.1177/1947601910373795 – ident: e_1_2_7_23_1 doi: 10.1093/nar/gkn923 |
SSID | ssj0017375 |
Score | 2.3535416 |
Snippet | Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to multiply... Abstract Melanoma is the most dangerous form of skin cancer with a very poor prognosis. Melanoma develops when unrepaired DNA damage causes to skin cells to... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 427 |
SubjectTerms | adhesion Apoptosis Cell adhesion Cell adhesion & migration Cell migration Cell viability DNA damage invasion Invasiveness MAP kinase MAPK pathway Matrix metalloproteinase Medicinal plants Melanoma Metastases Metastasis migration Plumbagin Reactive oxygen species Signal transduction Skin cancer Tumor cell lines Tumors |
Title | Elucidation of the effect of plumbagin on the metastatic potential of B16F10 murine melanoma cells via MAPK signalling pathway |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fexd.14079 https://www.ncbi.nlm.nih.gov/pubmed/32012353 https://www.proquest.com/docview/2389505330 https://search.proquest.com/docview/2350910646 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPVRcgJZXoCCDOHBJlcSxHYtToVtVoEUIUWkPSJGf0qrdZMVmeR347Xich1oQEuISJfLE77Fn7JlvAJ4jxJqXBUvLwlbh4YpU8dKk0ljppQ8KdIa-w_N3_Oy8fLNgix14OfrC9PgQ04EbckZcr5HBld5cYXL3zQY2zwQ67-VUoDnXyYcJOioXNILsZjJozFxkbEAVQiue6c_re9EfAuZ1eTVuOKe34NNY1d7O5OJo2-kj8-M3FMf_bMttuDkIouS4nzn7sOOaA9ibD1ftd-Dn7HJrln3EJdJ6EgRF0ht_4Nc6rGkaAxyRkIpJK9cpdE5aGrJuOzRBCpkHwlc5Dzo7WeGhPlJdqqZdKYL3BRvyZanI_Pj9W4JWJCqigxMMkfxVfb8L56ezj6_P0iFYQ2ooozItpJFCl1UhFde2KpXNlWdaViUzFeeF1Na7klGPIUGzXGljM8OUDSqLL40T9B7sNm3jHgCxhjmqjBey8iEfKhll2nkX1grBtRIJPBuHrV73mBz1qMuEnqxjTyZwOA5oPbDlpg7yiWTofZwl8HRKDgyFrVaNa7dIE2UoXvIE7vcTYSqFFtG3mCbwIg7n34uvZ4uT-PLw30kfwY0CtfloF3QIu93nrXscRJ5OP4lz-xd8J_wg |
link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIkEvvEsDBQziwCVVNn4klrgUutVCuxVCrbQXFNmOLa3oJiuaBdpDf3s9zkMUhIS4RIk88XvsGXvmG4DXCLHmZMpjlpa5f9g0VoKZWJpSOum8Ap2g7_D0SExO2McZn63B294XpsWHGA7ckDPCeo0MjgfSv3C5_Vl6Pk8yeQNuenanGLhh7_MAHjXKaIDZTaTXmUWW8A5XCO14hl-v70Z_iJjXJdaw5ezfhS99ZVtLk687q0bvmIvfcBz_tzX34E4ni5LddvLchzVbPYBb0-62_SFcjk9XZt4GXSK1I15WJK39B34t_bKmMcYR8amYtLCNQv-kuSHLukErJJ-5J3w3El5tJws810eqU1XVC0XwyuCMfJ8rMt39dEDQkEQFgHCCUZJ_qPNHcLI_Pn4_ibt4DbGhnMo4lUZmmuWpVEKXOVPlSDmuZc64yYVIpS6dZZw6jAqajJQ2ZWK4Kr3W4pixGd2E9aqu7BaQ0nBLlXGZzJ3Ph0pOubbO-uUiE1plEbzqx61YtrAcRa_O-J4sQk9GsN2PaNFx5lnhRRTJ0QE5ieDlkOx5ClutKluvkCaIUYKJCB63M2EohabBvZhG8CaM59-LL8azvfDy5N9JX8DtyfH0sDj8cHTwFDZSVO6DmdA2rDffVvaZl4Aa_TxM9CstEwBH |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFH4qRaq4sC-BAgZx4JIqEy-JxanQGRXKVBWi0hyQIq_SiE4yohm2A78dP2cRBSEhLlEiv8Sxn5_9PfstAM8wxJqXOU9ZbstwcXmqBDOpNFZ66YMCnaHv8PxYHJ6yNwu-2IIXgy9MFx9i3HBDyYjzNQr42vpfhNx9tUHMs0JegstMBOSLiOjdGDtqUtAYZTeTQWUWRcb7sEJoxjO-enEx-gNhXgSsccWZXYMPw792hiYf9zat3jPffwvj-J-NuQ5XeyRK9ruhcwO2XH0Tdub9Wfst-DE925hll3KJNJ4EpEg66w98WodJTWOGIxJKsWjlWoXeSUtD1k2LNkjh44Hw5UQEpZ2scFcfqc5U3awUwQODc_J5qch8_-SIoBmJiuHBCeZI_qK-3YbT2fT9q8O0z9aQGsqpTHNpZKFZmUsltC2ZshPluZYl46YUIpfaesc49ZgTNJsobWxmuLKBc54ZV9A7sF03tbsHxBruqDK-kKUP36GSU66dd2GyKIRWRQJPB7ZV6y4oRzUoM6Enq9iTCewODK16uTyvAkCRHN2PswSejMVBorDVqnbNBmkiiBJMJHC3GwhjLTSPzsU0geeRnX-vvpouDuLN_X8nfQw7Jwez6u3r46MHcCVHzT7aCO3Cdvtp4x4G-NPqR3GY_wQxa_7n |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elucidation+of+the+effect+of+plumbagin+on+the+metastatic+potential+of+B16F10+murine+melanoma+cells+via+MAPK+signalling+pathway&rft.jtitle=Experimental+dermatology&rft.au=Alem%2C+Fatima%E2%80%90Zahra&rft.au=Bejaoui%2C+Meriem&rft.au=Villareal%2C+Myra+O.&rft.au=Rhourri%E2%80%90Frih%2C+Boutayna&rft.date=2020-04-01&rft.issn=0906-6705&rft.eissn=1600-0625&rft.volume=29&rft.issue=4&rft.spage=427&rft.epage=435&rft_id=info:doi/10.1111%2Fexd.14079&rft.externalDBID=10.1111%252Fexd.14079&rft.externalDocID=EXD14079 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0906-6705&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0906-6705&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0906-6705&client=summon |